SAN FRANCISCO, CalifGenentech has submitted an application to the FDA for expanded use of bevacizumab(Drug information on bevacizumab) (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel(Drug information on paclitaxel) had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.
